Background

Tom Oxley is an Australian neurologist who founded Synchron in 2016, establishing the company at the nexus of vascular neurology and neuroengineering. His clinical background in interventional neuroradiology positioned him uniquely to envision a catheter-based approach to brain-computer interfaces.

Stentrode Innovation

Oxley conceived the Stentrode concept, a fundamental innovation in BCI methodology. Rather than requiring open cranial surgery to implant recording electrodes, the Stentrode is delivered through the patient’s native vascular system via standard neuroradiology catheter techniques. This approach leverages existing procedural expertise and infrastructure in interventional radiology.

Clinical Evidence

Under Oxley’s leadership, Synchron has demonstrated functional motor control in human patients, proving that endovascular electrode positioning can achieve signal quality comparable to penetrating arrays. His clinical intuition about vascular access pathways has been validated by successful human implants and growing FDA engagement.

Strategic Partnerships

Oxley has cultivated backing from prominent philanthropies and technology companies, including the Bill and Melinda Gates Foundation and partnerships with Apple and NVIDIA. These relationships reflect confidence in the endovascular approach and suggest pathways toward consumer integration of brain-computer interfaces.